First AD

Second AD

Genetic Screening for IgAN

Up to 15% of IgA nephropathy (IgAN) cases are considered familial, should. Should family members of individuals with IgAN be screened or monitored for signs of the disease? If yes, how often?

Videos

Video Series

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Advancing IgAN Care: Exploring the Next Wave of Treatments

Familial IgA nephropathy (IgAN) accounts for up to 15% of cases, raising questions about the need for screening among family members. While there is no consensus on routine screening, some experts suggest monitoring first-degree relatives, especially if they exhibit symptoms or have a family history of kidney disease. The frequency of monitoring is not standardized, but periodic assessments may be beneficial. Genetic counseling could also be considered to evaluate the risk and guide family members on potential preventive measures and lifestyle modifications.

Panelists discuss the importance of screening and monitoring family members of individuals with IgA nephropathy, noting that up to 15% of cases are familial and outlining recommendations for the frequency of such assessments.

Overview of IgAN and Its Common Symptoms

IgAN Progression

IgAN vs Other Glomerular Diseases

Biomarkers for IgAN

Impact of IgAN on Quality of Life

Misdiagnosis and Barriers to Early Detection of IgAN

Differential Diagnoses of IgAN

Significance of Proteinuria for Potential IgAN

Proteinuria Variability and IgAN Diagnosis

Biomarkers and Improving IgAN Diagnostic Accuracy

Primary Treatment Goals for Patients With IgAN

Proteinuria Reduction in Long-Term Kidney Damage Prevention

Symptoms Management and Targeting the Root Cause of IgAN